Related Experiment Video
Updated: Jan 14, 2026
A Protocol for Roux-en-Y Gastric Bypass in Rats using Linear Staplers
Published on: August 21, 2021
Ten‑Year Results of a Randomized Trial Comparing Banded Roux‑en‑Y Gastric Bypass to Sleeve Gastrectomy for Type 2
Megan Elizabeth Grinlinton1, Preekesh Patel2, Anamitra Nair2
1Department of General Surgery, Te Whatu Ora Waitematā, Auckland, New Zealand. megan.grinlinton@gmail.com.
Background:
Laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic sleeve gastrectomy (LSG) are common bariatric procedures that are effective in treating type 2 diabetes (T2D) in patients with obesity. The addition of a silastic-ring (SR) to LRYGB may increase weight loss, reduce weight regain, and improve diabetes remission. Five and seven-year results from a prospective, randomized, parallel, two-arm, clinical trial at North Shore Hospital (Auckland, Aotearoa New Zealand) found that SR-LRYGB was superior to LSG for diabetes remission and weight loss following surgery, with acceptable complication rates. Results on longer-term outcomes are still emerging in the literature.
Methods:
A 10-year analysis was conducted on 114 patients with T2D who underwent SR-LRYGB or LSG. The primary outcome was diabetes remission assessed at 10 years. Secondary outcomes included percentage total body weight loss (%TWL) and complications.
Results:
Of 114 patients randomized to either SR-LRYGB or LSG, 10 years after surgery, diabetes remission was seen in 15/49 (30.6%) after SR-LRYGB and 7/40 (17.5%) after LSG (adjusted OR 3.3; 95% confidence interval (CI) 1.0, 10.6; p = 0.042). Percentage total body weight loss was greater after SR-LRYGB than LSG (27.2% vs. 20.2%, absolute difference 7.0% 95% CI 2.2%, 11.8%; p = 0.005). Late minor complication rates were 28.6% after SR-LRYGB and 19.0% after LSG (absolute difference 9.6%, p = 0.226). Late major complication rates were 25.0% after SR-LRYGB and 31.0% after LSG (absolute difference 6.0%, p = 0.535).
Conclusions:
SR-LRYGB remains superior to LSG for diabetes remission and weight loss at 10 years following surgery. This study confirms long-term enhanced patient outcomes in patients undergoing SR-LRYGB when compared directly with LSG. This study adds to the mounting body of evidence that demonstrates sustained diabetes remission and weight loss in patients undergoing SR-LRYGB.
